Gemma Salvadó

@gsalvado.bsky.social

Leader of the Neuroimaging group at @barcelonabeta & @fpmaragall / Associate researcher at @biofinder_study, Lund University #Alzheimer #biomarkers

Happy to see this massive collaboration out covering 12 different cohorts including almost 3,000 cognitively unimpaired individuals. Plasma p-tau217 can be used to detect preclinical Alzheimer’s, but positive predictive values increase if +ve results are confirmed with CSF or PET

@biofinder.bsky.social · 11mo ago

🚨Paper alert🚨 New publication in JAMA Neurology led by @gsalvado.bsky.social. In a multicentric study, we examined the clinical utility to assess preclinical #Alzheimer’s disease in cognitively unimpaired individuals. jamanetwork.com/journals/jam... A 🧵...

Excited to share our review on the latest developments in neuroimaging in #Alzheimer’s disease . Great resource to be up to date!

Julie Ottoy@ottoyjulie.bsky.social · 11mo ago

🔥Recent advances in #neuroimaging of #Alzheimers disease 🧠✨ dx.doi.org/10.1002/alz.... ➡️ Valuable resource for both researchers & clinicians! ➡️ ATNIV biomarkers, staging, connectomics & more ➡️ Plus: how are sex & country represented in first/last authorship? @istaart.bsky.social Neuroimaging PIA

A next-generation blood test could personalize Alzheimer's treatment by revealing disease progression—not just diagnosis. BrightFocus Foundation grant recipient, Dr. Gemma Salvadó, helped validate this test to identify ideal candidates for anti-amyloid therapies. 🔬 Full story ⬇️

New Blood Test Could Personalize Alzheimer's Treatment Like Never Before

A new Alzheimer's blood test may reveal how far the disease has progressed and identify who's most likely to benefit from anti-amyloid therapies.

brightfocus.org

New paper published today in @nataging.nature.com ! This one took some time but it's always a pleasure working hand in hand with Laia Montoliu-Gaya and the Gothenburg team. Thanks also to the McGill group for also collaborating with TRIAD data. A 🧵 below. #ENDALZ

@biofinder.bsky.social · 12mo ago

🚨New publication in Nature Aging🚨 Co-led between Laia Montoliu-Gaya and @gsalvado.bsky.social. We measured several tau peptides in blood and assess their different relationships with Alzheimer’s disease stages. nature.com/articles/s43... 🧵

Today I will present our work titled: Biological staging of AD with the novel plasma eMTBR-tau243 and %p-tau217 🪧Insights into disease trajectory and biological staging of AD (session) 🕑 2PM 📍 Room 105 (even if it's not in the app) Don't miss it, it will be a great session! #AAIC2025

🚨 Heading to @EANM_NucMed meeting in Barcelona this fall? Don’t miss our special session on the future of PET imaging in the era of emerging Alzheimer’s disease treatments. Join the discussion on what’s next and why it matters #EANM2025 #Neuroimaging #Alzheimers

Barcelonaβeta Brain Research Center@barcelonabeta.bsky.social · last yr.

We have a date on October 7!🧠 We are organising the event "Clinical Use of PET in Alzheimer's Disease: Challenges & Opportunities" We'll bring together experts in the field of nuclear medicine and #Alzheimer's to explore the latest developments in PET imaging techniques.

🚨New paper in Alzheimer's & Dementia! We investigate whether p-tau immuno-assays selectively quantifying low-molecular-weight (LMW) tau (CNS) are more specific for tau changes in AD vs ALS than assays not differentiating between LMW and high-MW (PNS) tau👇https://pubmed.ncbi.nlm.nih.gov/40289884/

🔵🔬El alzheimer ya se puede diagnosticar precozmente con un análisis de sangre. El test ya está a punto para utilizarse de manera rutinaria en los hospitales, y no solo con fines de investigación como hasta ahora. www.lavanguardia.com/ciencia/2025...

El alzheimer ya se puede diagnosticar precozmente con un análisis de sangre

Un análisis de sangre permite diagnosticar la mayoría de casos de alzheimer de manera precoz, cuando los afectados tienen síntomas incipientes de deterioro cognitivo,

lavanguardia.com

Huge development towards a precise and scalable diagnosis of #Alzheimer's disease. Plasma MTBR-tau243 is more strongly associated with aggregated tau pathology and cognitive function than 🩸 p-tau217. Suggesting similar results than tau-PET with significantly lower costs and burden for patients

@biofinder.bsky.social · last yr.

‼️New publication on a novel plasma biomarker for tau pathology 🧠🧪 in @naturemedicine.bsky.social led by Kanta Horie & @gsalvado.bsky.social: 📖 www.nature.com/articles/s41... In this study, we investigated plasma eMTBR-tau243, which closely reflects tau tangle pathology in Alzheimer’s disease (AD).

🚨New paper published in @alzdemjournals! doi.org/10.1002/alz.14600 PhD student Linda Karlsson et al. use machine learning (ML) to predict tau-PET composites from accessible and inexpensive modalities: plasma biomarkers, structural MRI and clinical variables. Details 👇

Machine learning prediction of tau‐PET in Alzheimer's disease using plasma, MRI, and clinical data

INTRODUCTION Tau positron emission tomography (PET) is a reliable neuroimaging technique for assessing regional load of tau pathology in the brain, but its routine clinical use is limited by cost an...

doi.org